

**List of Measures under Consideration by the Centers for Medicare and Medicaid Services for December 1, 2015**

**Submitted by the Society of Gynecologic Oncology**

<b>MUC ID</b>	<b>Measure Title</b>	<b>Description</b>	<b>Measure Type</b>	<b>CMS Program(s)</b>
MUC15-450	Intraperitoneal chemotherapy administered within 42 days of optimal cytoreduction to women with invasive stage III ovarian, fallopian tube, or peritoneal cancer	Measuring the percentage of patient who received Intra Peritoneal (IP) chemotherapy after the debulking of advanced epithelial ovarian cancer	Process	MIPS
MUC15-452	Minimally invasive surgery performed for patients with endometrial cancer	Proportion of patients who underwent minimally invasive hysterectomy for endometrial cancer	Process	MIPS
MUC15-454	Platin or taxane administered within 42 days following cytoreduction to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer	Measuring the percentage of patient who received Intra Venous (IV) chemotherapy after the debulking of advanced epithelial ovarian cancer	Process	MIPS
MUC15-459	Surgical staging with lymph node removal for any grade 3 and/or myometrial invasion >50% with endometrial cancer	Uterine cancer patients with adequate surgical staging performed with a grade 3 tumor and deep uterine wall invasion.	Process	MIPS
MUC15-460	Use of brachytherapy for cervical cancer patients treated with primary radiation with curative intent.	The percentage of cervical cancer patients who undergoing curative intent radiation who receive brachytherapy in addition to external beam therapy	Process	MIPS
MUC15-461	Completion of external beam radiation within 60 days for women receiving primary radiotherapy as treatment for locally advanced cervical cancer (LACC)	Percentage of patients with locally advanced cervical cancer who complete their chemoradiation in 60 days or less	Process	MIPS

MUC15-463	Use of concurrent platinum-based chemotherapy for patients with stage IIB-IV cervical cancer receiving primary radiation therapy.	Percentage of patients who receive concurrent platinum-based chemotherapy for patients with stage IIB-IV cervical cancer receiving primary radiation therapy.	Process	MIPS
MUC15-465	Performance of radical hysterectomy in patients with IB1-IIA cervical cancer who undergo hysterectomy.	Performance of appropriate type of hysterectomy in women with early stage cervical cancer undergoing hysterectomy.	Process	MIPS
MUC15-466	Postoperative pelvic radiation with concurrent cisplatin-containing chemotherapy with (or without) brachytherapy for patients with positive pelvic nodes, positive surgical margin, and/or positive parametrium.	Proportion of patients with pelvic lymph node metastases, positive surgical margins, or positive parametrium who received postoperative pelvic radiation with concurrent cisplatin-containing chemotherapy (with or without brachytherapy)	Process	MIPS